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Abstract
Treatment fidelity is the use of methodological strategies to monitor and enhance reliability and validity of behavioral
intervention trials. Despite availability of guidelines and checklists, treatment fidelity remains underreported, hindering
evaluation, interpretation, and cross-study comparisons. Treatment fidelity is particularly important for music interventions
given the inherent complexity of musical stimuli and flexibility required for tailored delivery. The purpose of this paper is
to define and describe treatment fidelity strategies for our trial of a music-based play intervention for young children with
cancer and parents grounded in the NIH Behavior Change Consortium Treatment Fidelity Recommendations. We report
strategies for all 5 areas: study design, training providers, delivery of treatment, receipt of treatment, and enactment of
treatment skills. We also discuss 4 challenges our team encountered, including: (1) standardizing live music delivery, (2)
defining boundaries for tailored intervention delivery, (3) managing extended time between participants, and (4) minimizing
risk for bias. This paper expands on current fidelity literature and may provide a working model for other investigators
examining dyadic and/or active music interventions.
Keywords
music therapy, treatment fidelity, music intervention, behavioral intervention, dyadic intervention
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Introduction
Treatment fidelity is important to the design and conduct of
rigorous clinical research. In 2004, the National Institutes
of Health Behavior Change Consortium (NIH BCC)
defined treatment fidelity as “. . .methodological strategies
used to monitor and enhance the reliability and validity of
behavioral interventions. [Treatment fidelity] also refers to
the methodological practices used to ensure that a research
study reliably and validly tests a clinical intervention.”1
These practices help to ensure that changes seen posttreatment can be attributed to the intervention under
investigation rather than external factors and reduce the
chances of Type I and II errors.2 To encourage uptake and
use of these recommendations, consortium authors published a validated treatment fidelity checklist for use in

trial design and evaluation,3 with an updated checklist2
published in 2011.
Despite NIH BCC guidelines and checklist availability,
treatment fidelity continues to be under-reported in published research.1-3 Prior reviews indicate that publishing
authors often report details about treatment delivery, while
other areas such as treatment receipt and enactment are
rarely reported.4,5 In addition, there is inconsistent use of
standardized NIH BCC treatment fidelity definitions and
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Table 1. NIH BCC Components and Definitions.
NIH BCC definition1

Treatment fidelity component
Study design
Training providers
Delivery of treatment
Receipt of treatment
Enactment of treatment skills

Study design procedures ensure that a study can adequately test its hypotheses in
relation to underlying theory and clinical practices.
Standardized provider training includes procedures to ensure that interventionists
have been satisfactorily trained to deliver the intervention to study participants.
Treatment delivery procedures monitor and improve delivery of intervention and
comparison conditions; ensuring that treatment is delivered as intended.
Treatment receipt focuses on the participant and includes procedures to assure
that the treatment was both received and understood.
Enactment of treatment skills includes processes to monitor and improve
participant ability to perform treatment-related behavioral skills and cognitive
strategies in relevant real-life settings as intended.

reporting categories, which contributes to these observed
inconsistencies in reporting.5 The resulting absence and
inconsistency of reporting make evaluation, interpretation,
and cross-study comparisons difficult.
Treatment fidelity is especially important for music
interventions given the inherent complexity of musical
stimuli6,7 and flexibility required for delivery of tailored
interventions.8 A scoping review of music intervention
reporting quality revealed that only 20% of identified studies described strategies to ensure consistent treatment delivery across participants and providers—emphasizing the
need for publications that detail selection and use of treatment fidelity strategies for music intervention trials.9 To
date, there have been 3 publications detailing NIH BCC
guideline implementation in music intervention trials.6,10,11
Implementation of the NIH BCC recommendations requires
that investigative teams interpret, define, and select strategies that consider the unique context, attributes, and design
features of their trial. As such, published manuscripts
describing selection and implementation of specific fidelity
strategies help other investigators increase rigor in their
own trials.
The purpose of this paper is to define and describe
treatment fidelity strategies being used in our multisite
randomized controlled trial of a music-based play intervention for young children with cancer and their parents
(R01NR019190). This manuscript expands on current
fidelity literature and may provide a working model for
other studies investigating dyadic and/or active music
interventions.

Overview of the BIO-MUSE Trial
The Biologic Mechanisms and Dosing of Active Music
Engagement (BIO-MUSE) trial is a 2-group single-blind
randomized controlled trial examining the use of music
play to manage distress and improve health outcomes in
young children with Acute Lymphoblastic Leukemia
(ALL) and their parents (R01NR019190). Children and

one parent (enrolled as dyads) are stratified and randomized in blocks of 4 to the Active Music Engagement
(AME) intervention or Audio-Storybooks (ASB) attention
control condition. Child/parent dyads are stratified by
child age (preschoolers 3-5 years.; school-agers 6-8 years.),
site (Riley Hospital for Children at Indiana University
Health, Indianapolis, Indiana; Ann & Robert H. Lurie
Children’s Hospital, Chicago, Illinois; Children’s Mercy
Hospital, Kansas City, Missouri), and ALL risk level (standard risk; high risk). Both the intervention and attention
control conditions are standardized, and each group
receives one 30-minute AME or ASB session during
weekly outpatient clinic visits for the duration of the consolidation phase of ALL treatment (4 sessions for standard
risk participants; 8 sessions for high-risk participants). The
purpose of the BIO-MUSE trial is to examine biological
mechanisms of effect and explore dose-response relationships of AME on child/parent stress during the consolidation phase of ALL treatment.

Methods
In this paper we describe treatment fidelity strategies specific to the BIO-MUSE trial and their grounding in the NIH
BCC Treatment Fidelity Recommendations.1 Table 1 provides definitions for each of the 5 NIH BCC Treatment
Fidelity components. We then provide an overview for each
component and rationale for selected strategies.

Area 1: Study Design Strategies
Treatment fidelity strategies specific to study design help
ensure that the investigative team can adequately test their
proposed hypotheses in relation to underlying theory and
clinical processes. Selected strategies are unique to each
study and increase rigor by ensuring that: (1) interventions
are congruent with relevant theory and clinical practice; (2)
dosing is consistent within and across study conditions;
and (3) implementation setbacks are minimized.1 Table 2
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Table 2. Treatment Fidelity Strategies for Study Design.
Goal

NIH BCC description1

BIO-MUSE strategies

Goal 1: Ensure that
interventions are
congruent with
relevant theory and
clinical experience.

Operationalize interventions
to reflect theory; define
independent and dependent
variables most relevant to
the “active ingredient” of the
intervention.

Intervention theory: Contextual Support Model of Music Therapy12;
Self-Determination Theory13
Essential intervention elements: Intervention designed to provide
optimal levels of structure, autonomy support, and support
parent/child relationship through tailored delivery of music-play.
Attention control condition: Designed to control for audio-visual
stimulation, presence of a trained provider, and shared play
activity that involves both parent and child.14

Goal 2: Ensure same
treatment dose
within and across
conditions.

Ensure that treatment “dose”
(measured by number,
frequency, and duration) is
adequately described and is
the same for each subject
within and across treatment
and control conditions.

Number/frequency of sessions: Coincide with timing and length of
consolidation treatment (4 weekly sessions standard risk patients;
8 weekly sessions high risk patients).
Session duration: 20 min/session for ASB; 25 min for AME
Between session engagement: Activity kits encourage engagement in
condition-related activities outside sessions.
Dose monitoring via provider field note: Providers document actual
session length and participant-reported use of condition related
activities between sessions.
Dose confirmation: External quality assurance monitoring confirms
provider-reported field note data.

Goal 3: Plan for
implementation
setbacks

Address possible setbacks in
implementation.

Train Multiple Providers at each study site to ensure provider
availability and minimize impact of turnover, absences, and illness.

summarizes the goals of treatment fidelity specific to study
design, with corresponding strategies for the BIO-MUSE
trial. In the sections that follow, we elaborate on our selection of study-specific strategies.

Goal 1: Ensure Interventions are Congruent
With Relevant Theory and Clinical Experience
In theory-driven research design, the selected theory
informs 3 aspects of study design: 1) selection of intervention content (ie, essential elements), 2) specified relationship between independent and dependent variables, and 3)
selection of outcome measures. The NIH BCC guidelines
specify that the theoretical model underlying the intervention must be clearly described, with subsequent checklists
created to support implementation.1-3
Theory-informed essential content. In previous publications,
we have outlined how the AME intervention aligns with the
Contextual Support Model of Music Therapy (CSM-MT12)
which is grounded in Self-Determination Theory.13 The
CSM-MT explains how music can be used to create a supportive environment by offering optimal levels of structure,
autonomy support, and relationship support.15
In brief, we know that attributes of the environment play
an important role in whether an individual perceives a situation to be stressful or benign, and how they respond behaviorally to that situation (engagement vs disaffection).12,16-22

Engagement is a necessary precursor to learning and enactment of positive coping strategies, such as the use of music
play to manage cancer-related stress.18-21,23 The AME
intervention was designed to mitigate qualities of stressful
environments, like cancer treatment.12,17,18,24 Stressful
environments are unpredictable, constrain autonomy, and
often lack or strain social support. In contrast, supportive
environments are structured, provide opportunities for
choice/control, and offer relationship support. Through tailored delivery of shared music experiences, the AME intervention creates a supportive environment using familiar
music play (structure), child-directed experiences (autonomy support), and supportive child/parent interaction (relationship support).12,16,17 Supportive environments lead to
higher engagement and subsequent acquisition and use of
positive coping strategies.12,16,17,19-21 Music play is particularly viable for children ages 3 to 8 years because young
children cope with stressful experiences through play,25 and
music can offer a sense of normalcy through shared, meaningful experiences that focus on healthy aspects of the
child and family.26-28 Table 3 shows the relationship of
essential AME intervention content to CSM-MT theoretical principles.
Attention control design. We have previously established the
ASB condition as a feasible and acceptable control condition for patients and families.12,16,17 The ASB condition
controls for (1) audio-visual stimulation; (2) presence of a
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Table 3. Active Music Engagement Intervention Components and Theoretical Principles.*.
Intervention component

Theoretical principles

Component 1:
Music-based play
activities

(1) Predictable environments provide structure that supports child competence.
Therapist uses familiar music activities to provide structure and increase child’s ability to predict
what will happen in their environment.
(2) Leveled activities help ensure success and support child competence.
Therapist tailors physical activity requirements to meet the individual needs of each child. Enables
child success and engagement during periods of high or fluctuating symptom distress.
(3) Opportunities to make independent decisions support child autonomy.
Child chooses from a variety of music play activities, and each activity includes a wide range of
materials. Activities include a wide range of materials and activity options so child can make
choices for self and others.
Therapist uses improvisational techniques to follow child-initiated changes in their music making
(eg, child changes tempo or style of playing).
(4) Activities structured to support caregiver-child interaction.
Activities are designed to structure and support reciprocal caregiver-child interactions. Therapist
individualizes experiences to support increased frequency and quality of interactions.

Component 2: Music
play resource kit

Supports independent use of music play to manage distress between therapist-led sessions.
Activities mirror content from therapist-led sessions. The kit includes:
(1) P
 rofessional audio recording of music composed and/or arranged specifically for the AME
intervention.
(2) Age-appropriate musical instrument and play materials that correspond to each activity.
(3) A
 ctivity cards designed to give children/caregivers information “at-a-glance” on ways they can
use their kit.

Component 3: Session
planning and caregiver
tip sheets

(1) P
 romotes caregiver competence about how children use play to cope and ways to engage their
child in music play during transplant.
(2) P
 romotes caregiver autonomy by empowering caregivers with skills/resources to support their
child during treatment
(3) Supports caregiver-child relationships through normalizing, music-based play activities

*Table reprinted with permission in accordance with creative commons open access license “Attribution-NonCommercial 4.0 International” (CC BYNC 4.0) http://creativecommons.org/licenses/by-nc/4.0/ for the following publication: Russ KA, Holochwost SJ, Perkins SM, et al. Cortisol as an acute
stress biomarker in young hematopoietic cell transplant patients/caregivers: active music engagement protocol. JACM. 2020;26(5):424- 434.

trained provider; and (3) shared activity between parent and
child.
Conceptual framework and measures selection. Our conceptual framework is based on Robb’s Contextual Support
Model of Music Therapy,12,18 Self-Determination Theory,13
and further informed by Kazak and Baxt’s Pediatric Medical Traumatic Stress Model,29 which provides a useful heuristic for understanding short- and long-term consequences
of pediatric cancer treatment for parents and their children. These theories, and the resulting model, directly
informed our selection of covariates, mediators, and outcome measures.

Goal 2: Ensure Same Treatment Dose Within
and Across Conditions
Our BIO-MUSE protocol specifies condition frequency,
duration, and schedule for participants in both conditions.
Regardless of condition, children with standard risk ALL

receive 4 weekly sessions during the consolidation phase of
treatment, whereas children with high risk ALL receive 8
weekly sessions. The number of sessions is based on
Children’s Oncology Group (COG) approved treatment
protocols, which vary based on ALL risk level. The decision to see participants for the full duration of their treatment is grounded in ethical and practical considerations,
including justice and non-maleficence. Providing support
for the full treatment course for standard risk participants
and for only half of the treatment course for high-risk participants would be inadequate and potentially harmful.
The NIH BCC guidelines recommend equivalent dosage
between study conditions. In previous AME trials, the AME
and ASB conditions were delivered in an in-patient setting
and had an equal duration (45 minutes, with 30 minutes of
music or stories). The current trial takes place in the outpatient clinic setting. To accommodate clinic flow and patient
needs we needed to limit session duration to 30 minutes or
less. As such, total session duration for AME sessions is
30 minutes total (5 minutes collaborative goal setting;

MacLean et al
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Table 4. Treatment Fidelity Strategies for Training Providers.
NIH BCC description1

BIO-MUSE strategies

Goal 1: Standardize
training.

Ensure that training is conducted in same
manner by different providers.

Standardized study protocols and operating procedures (SOPs)
for study conditions, evaluation sessions, and blood/saliva
collection and storage.
Standardized Training including manuals, content, and schedule.
Evaluation of Training.

Goal 2: Ensure
provider and
evaluator skill
acquisition.

Train providers and evaluators to welldefined performance criteria.

Position descriptions detailing required skills, education, training,
and/or credentials for all study roles.
Role-playing as an essential part of training.
External quality assurance (QA) Monitoring with set criteria for
protocol adherence.

Goal 3: Minimize
“Drift” in Provider
and Evaluator Skills

Ensure that provider and evaluator skills
do not decay over time.

Self and external QA monitoring conducted on a predetermined
schedule for duration of trial.
Monthly Calls for team members based on role (providers; data
collectors).

Goal 4:
Accommodate
Provider
Differences

Ensure adequate level of training
in providers of differing skill
level, experience, or professional
background.

Individualized supervision through QA monitoring and monthly
team calls.
Signed position description which delineates minimum
competencies based on role.

Goal

20 minutes of music-play; 5 minutes educational content).
Total session duration for ASB is 20 minutes (5 minutes
set-up; 15 minutes audio-storybooks—the length of one storybook). Although total session length is not equivalent, the
amount of audio-visual stimulation is similar across groups,
with the additional 10 minutes in AME attributed to assessment and educational activities that are unique to that condition. In addition to in-person sessions, participants take
home a music-play or audio-storybooks kit to encourage
between-session use of the condition-related activities.
We monitor dose (frequency, duration) through providercompleted field notes that include the session date, session
begin/end times, and parent-reported kit use between sessions. Providers also audio- or video-record sessions which
provides an external validity check for data reported in the
provider field note. We also perform self and external quality assurance monitoring which are explained in greater
detail below (see Area 2—Goal 2: Ensure Provider Skill
Acquisition).

Goal 3: Plan for Implementation Setbacks
The BIO-MUSE protocol specifies plans for a variety of
possible implementation setbacks. Examples include training multiple music therapists and data collectors at each site
to minimize the impact of absence/illness or staff turnover
and providing paper copies of measures to data collectors in
the event of technology failure. Our team also meets weekly
to discuss ongoing participants and any issues with protocol implementation, which are then addressed with input
from the principal investigator (PI), site PIs, and core project manager.

Area 2: Training Providers
The use of standardized training programs helps to ensure
consistent delivery of study protocols across providers and
sites. These strategies are also important to address differences in providers’ educational training, clinical background, and experience. Table 4 summarizes provider
training goals and corresponding strategies for the BIOMUSE trial.

Goal 1: Standardize Training
Our providers and data collectors are trained on conditionspecific protocols and SOPs during training sessions led by
the PI and core project manager. Training session agendas,
content, and protocols are standardized to ensure consistent
training over the course of the trial. We have training manuals specific to each role including providers, site PIs, and
data collectors. All team members receive the same 1 hour
of core content including the study overview, theoretical
framework, clinical overview of ALL treatment, responsibilities and communication, identification and reporting of
adverse events, online database file management procedures, and strategies to minimize bias when discussing the
study. Provider and data collector manuals also include
standardized protocols for delivering study conditions or
conducting data collection. Site PIs have additional SOP
requirements for providing study oversight including Single
IRB requirements, recruitment, informed consent, billing,
and coordination of study activities. Total initial training
time varies based on role (4 hours for data collectors; 6 hours
for site PIs; 10 hours for providers). At the conclusion of

6
training, we ask team members to complete evaluations to
improve future training sessions.

Goal 2: Ensure Provider Skill Acquisition
Our providers are board-certified music therapists who
have a minimum of a bachelor’s degree in music therapy
and experience working in pediatric medical settings. Our
data collectors are hospital employees or research assistants
in a variety of roles including clinical research assistants,
nurse practitioners, and undergraduate students. We have
position descriptions for all study-related roles, specifying
minimum requirements for education, training, and experience, as well as competencies, responsibilities, and skills
needed to fulfill the role. The position description establishes the minimum skills required and communicates
expectations. All team members receive a role-specific
position description at the start of their training and sign the
position statement agreement after initial training is
complete.
Role-play is an essential feature of our training which
helps to ensure skill acquisition. We also use self and external QA monitoring to establish whether team members are
delivering essential elements of the study protocol with predetermined thresholds for initial and sustained protocol
adherence. During QA monitoring, providers (and data collectors) listen to their audio-recorded sessions and fill out
session-specific checklists listing essential content that
should be delivered for a specified session. An external
monitor also listens to sessions and completes the same
session-specific checklist. The threshold for initial protocol
adherence is >80% of all QA items during the last session
of a provider’s second AME participant, during the last session of a provider’s first ASB participant, or during the last
session of a data collector’s first participant. We monitor 2
AME participants to establish initial adherence due to the
increased complexity of AME sessions. External QA monitors schedule individual meetings to discuss any missed
items or challenges observed during monitoring. If a provider or data collector does not meet the initial adherence
threshold by the indicated timeline, self and external QA
monitoring continues until the threshold of 80% or more of
QA items has been met.

Goal 3: Minimize “Drift” in Provider Skills
Once providers and data collectors achieve the initial adherence threshold, we continue to engage in self and external
QA procedures using a priori monitoring schedules to minimize drift. The schedule for sustained monitoring specifies
completion of self and external monitoring for every fifth
participant (or 60 days, whichever comes first). All sessions
are audio-recorded to allow for unscheduled monitoring as
needed. In addition, all providers and data collectors attend
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monthly role-specific meetings to discuss study progress,
protocol implementation, and ongoing participants.
Meetings are essential to communicating study updates,
building a collaborative team environment, addressing
common challenges, sharing solutions, and promoting protocol adherence over time.

Goal 4: Accommodate Provider Differences
Providers receive individualized instruction during training
and individualized mentoring through ongoing quality
assurance monitoring. External QA monitoring facilitates
identification of any provider differences that might require
additional training and monitoring. The signed position
description (described above) also helps to ensure that providers meet minimum specified requirements (education,
certification, experience) and agree to deliver study conditions or conduct data collections sessions according to study
protocols.

Area 3: Delivery of Treatment
Treatment delivery strategies help ensure that study conditions are delivered as intended. Primary strategies include
the use of standardized treatment protocols and sustained
monitoring of provider delivery during the trial, with additional strategies to reduce within-treatment differences and
contamination between study conditions. Table 5 summarizes treatment delivery goals and corresponding strategies
for the BIO-MUSE trial.

Goal 1: Control for Provider Differences
We use several strategies to monitor and control for nonspecific treatment effects that may result from provider differences in terms of their perceived warmth or credibility. As
described earlier, all provider sessions are audio- or videorecorded to facilitate QA monitoring. In addition to protocol
adherence, external monitors also look at variations in provider delivery. When hiring study personnel, we look for
providers with experience working with young children and
parents in a hospital setting, and who demonstrate a supportive interaction style that embodies inclusivity and cultural sensitivity. In addition, we use the same providers
across study conditions to help control for therapist attributes and conduct qualitative interviews with parents that
include questions about their experience with the provider.

Goal 2: Reduce Differences Within Treatment
BIO-MUSE providers use manualized intervention protocols and session-specific checklists during condition delivery. The session checklists contain suggested language for
information delivery, reminders about specific intervention

MacLean et al
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Table 5. Treatment Fidelity Strategies for Delivery of Treatment.
NIH BCC description1

BIO-MUSE strategies

Goal 1: Control
for provider
differences.

Monitor and control for
subject perceptions of
nonspecific treatment
effects across
intervention and
control conditions.

Recorded sessions: All sessions audio- or video-recorded.
External QA monitoring: Includes provider interaction style and attributes.
Provider selection: Hire providers that demonstrate supportive interaction styles and
have experience working with young children and families.
Same providers: Providers deliver both intervention and attention control conditions.
Qualitative interviews: Provides parent perspectives about their experience with
providers.

Goal 2: Reduce
differences
within
treatment.

Ensure that providers
in the same condition
are delivering the
same intervention.

Standardized study protocols: Manualized protocols for each study condition.
Recorded sessions: All session audio- or video-recorded.
Self- and external QA monitoring: Monitoring ensures accurate and consistent delivery
across providers.
Standardized QA checklists: Lists essential elements for each study condition.

Goal 3: Ensure
adherence
to treatment
protocol.

Ensure that study
conditions are being
delivered as intended
including content and
treatment dose.

Self and external QA monitoring: Sustained monitoring ensures accurate and
consistent delivery of study conditions over time.
Standardized QA checklists: Lists essential elements for each study condition. Used
during session delivery and self/external QA monitoring.
Individualized supervision: Review omissions and/or protocol deviations with
providers on an individual basis.
Monthly provider calls: Review challenges and successes experienced during session
delivery; discuss protocol omissions or deviations.
QA checklists: Support protocol adherence/deviation tracking across providers and
study conditions.
Provider field notes: Providers capture date, time, and duration for study sessions in
electronic field notes.

Goal 4: Minimize
contamination
between
conditions.

Minimize contamination
across treatment/
control conditions,
especially when
implemented by same
provider.

Standardized study protocols: Manualized protocols for each study condition.
Recorded sessions: All session audio- or video-recorded.
Self and external QA monitoring: Monitoring ensures accurate and consistent delivery
without cross-contamination. Monitoring for biased language when answering
parent questions about study conditions.
Standardized QA checklists: Lists essential elements for each study condition. Used
during session delivery and self/external QA monitoring.
Theory/rationale for study conditions: Train providers on theory and rationale
underlying structure/delivery of intervention and low dose attention control
conditions.
Non-biased language training: Equip providers with non-biased language and
explanation to address participant questions about study conditions.

Goal

content, and a step-by-step guide to session flow. Checklists
help ensure consistent and complete delivery of content
identified as essential to each study condition. Differences
within treatment are also monitored during self and external
QA monitoring.

Goal 3: Ensure Adherence to Treatment Protocol
Protocol adherence is monitored through our previously
described QA monitoring procedures and session-specific
checklists. The external QA monitor reviews any omissions
and/or protocol deviations with providers on an individual
basis. Self and external QA checklists are computerized
and completed in our Research Electronic Data Capture
(REDCap30) study database (which is compliant with the
Health Insurance Portability and Accountability Act, or

HIPAA). This feature allows us to generate real-time reports
and easily track protocol adherence across sessions and providers. Providers also complete a study field note for each
session that includes treatment dose information (ie, session
date; session start/end times). The fieldnote is a part of our
REDCap study database allowing us to generate reports to
identify protocol deviations related to timing and duration
of intervention delivery.

Goal 4: Minimize Contamination Between
Conditions
We elected to use the same providers for intervention and
attention control conditions. This was done to help control
for provider differences across conditions, but this also creates opportunities for contamination (ie, essential elements
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Table 6. Treatment Fidelity Strategies for Receipt of Treatment.
Goal
Goal 1: Ensure participant
comprehension.
Goal 2: Ensure participant
ability to use cognitive
skills.
Goal 3: Ensure participant
ability to perform
behavioral skills.

NIH BCC description1

BIO-MUSE strategies

Ensure that participants understand
information provided during study
sessions, especially when participants
may be cognitively compromised, have
a low level of literacy/education, or
may not be proficient in English.
Ensure that participants can use
the cognitive skills taught in the
intervention.
Make sure that participants can use
the behavioral skills taught in the
intervention.

Assess comprehension: Providers use active listening, active
questioning, and behavioral observation to assess participant
comprehension and ability to use music play strategies.
Session planning sheet: Providers and parents establish areas of
needs and focus at the start of each session.
Parent education: Together, providers and parents review
music play strategies (including tip sheets) and identify athome implementation strategies.
Provider fieldnote & Likert Scales: Providers complete Likerttype scales and provide a narrative entry to document
parent and child involvement, understanding, and ability to
use content during sessions.
Document independent use: Provider documents parentreported use of play materials between study sessions
(frequency, duration, how materials were used), as well as
barriers and facilitators for use.

of intervention appearing in attention control sessions) and
risk of providers introducing bias that favors the intervention. In addition to sustained and rigorous QA monitoring,
our providers receive training on the theories and scientific
rationale that informed the content, structure, and delivery
of the intervention and attention control conditions. Provider
training also includes scenarios where unintended bias
might occur and how to address participant questions about
the study or their assigned condition. For example, when
describing our study, we share that we are interested in
learning how play activities like stories and music might be
helpful during cancer treatment—positioning AME and
ASB as equal experiences.

Area 4: Receipt of Treatment
Fidelity of treatment receipt involves strategies to ensure
that the treatment delivered is received by the participant.2
Receipt involves participants’ understanding and their ability to use and demonstrate skills learned in treatment or
control conditions. Limited understanding or ability to perform skills presented during treatment and control sessions
will interfere with evaluation of treatment effects. As such,
strategies for treatment receipt center on assessing comprehension and ability to use treatment-related skills. Table 6
summarizes treatment receipt goals and corresponding
strategies for the BIO-MUSE trial.

Goals 1 to 3: Ensure Participant Comprehension,
Ability to Use Cognitive Skills and Ability to
Perform Behavioral Skills
We train providers to use active listening, active questioning, and behavioral observation to assess parent and child
comprehension of intervention content. At the start of each
session, providers work with parents to identify areas of

need for their child through verbal dialog and use of a planning sheet. This supports parent-identification of needs for
their child and positions the provider as a collaborator. At
the close of sessions, providers (1) reference standardized
tip sheets; (2) engage parents in a reflective dialog about
what worked during the session (based on planning sheet
conversation); and (3) identify strategies the parent and
child can try using at home or in the hospital. Parents are
given copies of tip sheets to reinforce concepts and children
are given a music-play kit to encourage enactment of music
play strategies outside of study sessions. After sessions,
providers complete an electronic fieldnote that includes
Likert-type scales to capture parent and child engagement
and a narrative entry detailing behavioral observations, participant questions, and any events that may influence parent/child understanding and use of music play strategies
(eg, session interruptions, presence of other clinic staff).

Area 5: Enactment of Treatment Skills
Enactment of treatment skills involves strategies to assess,
monitor, and improve participants’ ability to perform and
use treatment-related skills (cognitive and behavioral) in
settings beyond study sessions. Borelli2 describes enactment as “. . .an important addition to the treatment fidelity
model because a distinction is made between what is actually taught (treatment delivery), what is learned (treatment
receipt) and what is actually used (enactment).” Table 7
summarizes enactment of treatment goals and corresponding strategies for the BIO-MUSE trial.

Goals 1 to 2. Ensure Participant Use of
Cognitive and Behavioral Skills
As mentioned under Area 4, providers use parent education
materials (ie, standardized tip sheets) and engage parents in
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Table 7. Treatment Fidelity Strategies for Enactment of Treatment Skills.
Goal
Goal 1: Ensure participant
use of cognitive skills.
Goal 2: Ensure participant
use of behavioral skills.

NIH BCC description1

BIO-MUSE strategies

Ensure that participants use the cognitive
skills provided in the intervention in
appropriate life settings.
Ensure that participants use the
behavioral skills provided in the
intervention in appropriate life settings.

Parent education: Together, providers and parents
review music play strategies (including tip sheets) and
identify at-home implementation strategies.
Music play kit: Children are given a kit to keep and use
at home (or other settings). It includes recorded
music, instruments, activity cards, and materials used
during provider-directed sessions.
Encourage use: Providers encourage participants to use
play materials between sessions.
Document independent use: Provider documents
parent-reported use of play materials between study
sessions (frequency, duration, how materials were
used), as well as barriers and facilitators for use.
Qualitative interviews: Provide details about parent
and child use of music play strategies and materials
outside study sessions.

reflective dialog about music play strategies, what works
for their child, and ways to use the play materials at home
(or in other settings) to manage stress. This individualized
and cooperative approach encourages active reflection and
use of materials outside sessions. Children are given a
music play kit to further encourage use of music play strategies to manage distress at home or in the hospital. Musicplay kits include recorded music, instruments, activity
cards, and materials used during provider-directed sessions.
The kits were developed and refined during initial pilot testing to establish their acceptability and use.17 At the close of
each session providers encourage self-directed use of play
materials (although it is never framed as a requirement).
Providers monitor and document use of materials between
study sessions (frequency, duration, how materials were
used), along with any barriers and facilitators for use.
Finally, we conduct qualitative interviews with parents at
study conclusion. Interviews provide more detailed descriptions about parent and child use of music-play strategies
and materials outside study sessions, and identification of
facilitators and barriers to use.

Discussion
The NIH BCC guidelines were developed to improve the
design and rigor of complex behavioral interventions.1
Music intervention trials are especially complex due to the
compositional features of music stimuli (rhythm, tempo,
pitch, harmonic structure, timbre may affect outcomes differentially), variety of music experiences (active music
making, music listening, songwriting), and other factors
unique to music interventions.6,7 Here we describe some of
the greatest challenges our team has encountered in both
design and early implementation of fidelity strategies for
the BIO-MUSE trial including: (1) standardizing live music

delivery; (2) defining boundaries for tailored intervention
delivery; (3) managing extended time between participants;
and (4) minimizing risk for bias.

Standardizing Live Music Delivery
In contrast to recorded music listening, the use of live music
introduces greater potential for variability in delivery across
study participants and providers. In the BIO-MUSE trial we
use pre-composed music activities with embedded improvised content that is tailored to meet the unique needs of the
child and parent. To reduce variability, we selected and
composed age-appropriate activities for use during sessions, specified strategies to facilitate improvised content,
and trained providers on theoretical principles to guide tailored delivery. To facilitate learning and consistent “performance” of the music activities, we provide sound recordings,
music notation, and detailed descriptions for each activity
in our protocols. During training, activities are modeled
using live demonstration and example videos and practiced
to establish competency. AME activities also use an improvisational approach to parent/child music-making. To help
standardize and support this improvisational approach we
use specific strategies to structure and support child/parent
musical interactions. For example, we use “call and
response” formats, steady rhythms for grounding, narrate
parent/child actions through improvised lyrics, and rhythm
matching.

Defining Boundaries for Tailored
Intervention Delivery
Tailored interventions have been defined as those that rely
on clinical judgment and adapt treatment to meet individual
needs.31,32 The AME intervention is tailored in 3 ways. First,
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the intervention uses collaborative goal setting at the start of
sessions. This provides focus for activity selection and tailored use of music to meet identified goals. Second, the
intervention includes a range of activities to support variations in child energy and distress while supporting child
autonomy through meaningful choices. The pacing, physical
activity requirements, and qualities of the music activity
can be adjusted to match immediate needs and modulated
over time to achieve desired goals. Finally, therapists are
trained to use theoretical principles of Self-Determination
Theory13 and the CSM-MT12 to guide clinical decision
making as they tailor the intervention (Table 3).
Determining how much flexibility can occur in a standardized protocol is challenging.32 Consistent with recommendations from O’Malley and Qualls,32 we specify a basic
structure for sessions including duration with recommendations for time spent in collaborative goal setting, active
music-making, and parent education. Time spent in each
area may vary based on parent or child needs. Variations are
monitored and documented.
To build therapist skills in tailored delivery, O’Malley and
Qualls32 recommend support and expert consultation during
trial implementation. For our team, this involves sustained
individualized QA monitoring from a board-certified
music therapist experienced in the protocol and monthly provider meetings led by the PI. Individual and group meetings
often focus on therapists’ decision-making processes as they
tailor the AME experience and “defining boundaries” of the
intervention. These conversations, along with session-specific fidelity checklists, help solidify theory-informed delivery and increased confidence with the tailoring process.

Managing Extended Time Between
Participants
An additional challenge is managing extended time between
participant accruals and the resulting need for increased self
and external QA monitoring.11 The incidence rate of ALL
is relatively low,33 affecting how frequently our providers
deliver study protocols and results in the need for more
frequent QA monitoring. This places greater demands on
therapists’ time and increases costs for compensation of
therapists and external QA monitors.1,2,10,11,32 This also
affects perceived burden by providers and study personnel
that can lead to burnout. Our core group of music therapists have published on their experience of QA monitoring
and its value for their own professional development.34
However, it has been essential to engage in sustained conversations about the importance of QA monitoring and
explore strategies to reduce burden.

Integrative Cancer Therapies
it as the music study. To address this concern, we refer to
our study as the “Music & Stories Trial” in our brochures
and during conversations with hematology/oncology professionals, clinical staff, patients, and families. In addition,
we provide ongoing staff in-services that include information about the trial and recommended language to reduce
bias when talking with families. Members of our study team
are also trained to present and talk about both conditions
using non-biased language during informed consent and
conversations with medical staff and families.
In closing, we recommend investigative teams use the
NIH BCC guidelines, along with related checklists, to
guide the design and selection of treatment fidelity strategies during study conceptualization.1-3 We also recommend
that investigators use published Reporting Guidelines for
Music-based Intervention Trials to inform standardization
of music experiences.7 The reporting guidelines discuss
attributes of music interventions that should be specified
and reported in music trials—making it an informative
resource as investigators work to specify essential features
and standardize delivery of both live and recorded music
interventions. Treatment fidelity is essential to research
integrity. Though treatment fidelity requires time and
added resources, the cost of not engaging in treatment
fidelity strategies is far greater.2 At the time of publication,
we found a limited number of publications explicating
treatment fidelity strategies for music intervention trials.
Dissemination, implementation, and transparency about
trial-specific fidelity strategies are important to advancing
the field, and we hope our trial may provide a working
model for other investigators examining dyadic and active
music interventions.
Authors’ Note
Amanda K. Henley is also affiliated to Purdue School of
Engineering and Technology, Indianapolis, IN, USA.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support
for the research, authorship, and/or publication of this article: The
BIO-MUSE trial is supported by the National Institutes of HealthNational Institute of Nursing Research R01NR019190 (Robb, PI).

ORCID iD
Jessica A. MacLean

https://orcid.org/0000-0001-5468-5875

References

Minimizing Risk for Bias
We identified potential risk for bias in how members of the
healthcare team talk about our trial, sometimes referring to

1. Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the NIH Behavior Change
Consortium. Health Psychol. 2004;23:443-451.

MacLean et al
2. Borrelli B. The assessment, monitoring, and enhancement
of treatment fidelity in public health clinical trials. J Public
Health Dent. 2011;71 Suppl 1:S52-S63.
3. Borrelli B, Sepinwall D, Ernst D, et al. A new tool to assess
treatment fidelity and evaluation of treatment fidelity across
10 years of health behavior research. J Consult Clin Psychol.
2005;73:852-860.
4. Jibb L, Nathan P, Stevens B, et al. Psychological and physical interventions for the management of cancer-related pain
in pediatric and young adult patients: an integrative review.
Oncol Nurs Forum. 2015;42:E339-E357.
5. O’Shea O, McCormick R, Bradley JM, O’Neill B. Fidelity
review: a scoping review of the methods used to evaluate
treatment fidelity in behavioural change interventions. Phys
Ther Rev. 2016;21:207-214.
6. Wiens N, Gordon RL. The case for treatment fidelity in
active music interventions: why and how. Ann N Y Acad Sci.
2018;1423:219-228.
7. Robb SL, Burns DS, Carpenter JS. Reporting guidelines
for music-based interventions. J Health Psychol. 2011;16:
342-352.
8. Bradt J. Randomized controlled trials in music therapy: guidelines for design and implementation. J Music Ther. 2012;
49:120-149.
9. Robb SL, Hanson-Abromeit D, May L, et al. Reporting quality of music intervention research in healthcare: a systematic
review. Complement Ther Med. 2018;38:24-41.
10. Baker FA, Tamplin J, Clark IN, Lee YEC, Geretsegger M,
Gold C. Treatment fidelity in a music therapy multi-site
cluster randomized controlled trial for people living with
dementia: the MIDDEL project intervention fidelity protocol.
J Music Ther. 2019;56:125-148.
11. Robb SL, Burns DS, Docherty SL, Haase JE. Ensuring treatment fidelity in a multi-site behavioral intervention study:
implementing NIH Behavior Change Consortium recommendations in the SMART trial. Psychooncology. 2011;20:
1193-1201.
12. Robb SL. The effect of therapeutic music interventions on
the behavior of hospitalized children in isolation: developing
a contextual support model of music therapy. J Music Ther.
2000;37:118-146.
13. Ryan RM, Deci EL. Self-Determination Theory: Basic
Psychological Needs in Motivation, Development, and
Wellness. Guilford Publications; 2017.
14. Freedland KE, King AC, Ambrosius WT, et al. The selection of comparators for randomized controlled trials of healthrelated behavioral interventions: recommendations of an NIH
expert panel. J Clin Epidemiol. 2019;110:74-81.
15. Russ KA, Holochwost SJ, Perkins SM, et al. Cortisol as an
acute stress biomarker in young hematopoietic cell transplant patients/caregivers: active music engagement protocol.
JACM. 2020;26:424-434.
16. Robb SL, Clair AA, Watanabe M, et al. A non-randomized
[corrected] controlled trial of the active music engagement
(AME) intervention on children with cancer.. Psychooncology.
2008;17:699-708.
17. Robb SL, Haase JE, Perkins SM, et al. Pilot randomized trial
of active music engagement intervention parent delivery for
young children with cancer. J Pediatr Psychol. 2017;42:
208-219.

11
18. Robb SL. Coping and chronic illness: music therapy for children and adolescents with cancer. In: Robb SL, ed. Music
Therapy in Pediatric Healthcare: Research and EvidenceBased Practice. Vol. 2003. American Music Therapy
Association; 2003; 101-136.
19. Skinner EA, Wellborn JG. Coping during childhood and
adolescence: a motivational perspective. In: Featherman DL,
Perlmutter M, eds. Life-Span Development and Behavior.
Lawrence Erlbaum; 1994, 91-133.
20. Skinner EA. Perceived Control, Motivation, and Coping.
Vol. 8. SAGE; 1995.
21. Skinner EA. Action regulation, coping, and development. In:
Brandtstadter J, Lerner RM, eds. Action & Self-Development:
Theory and Research Through the Life Span. SAGE; 1999;
465-503.
22. Compas BE, Connor-Smith JK, Saltzman H, Thomsen AH,
Wadsworth ME. Coping with stress during childhood and
adolescence: problems, progress, and potential in theory and
research. Psychol Bull. 2001;127:87-127.
23. Hildenbrand AK, Clawson KJ, Alderfer MA, Marsac ML.
Coping with pediatric cancer: strategies employed by children
and their parents to manage cancer-related stressors during
treatment. J Pediatr Oncol Nurs. 2011;28:344-354.
24. Robb SL. Designing music therapy interventions for hospitalized children and adolescents using a contextual support model of music therapy. Music Ther Perspect. 2003;21:
27-40.
25. Ginsburg KR. The importance of play in promoting healthy
child development and maintaining strong parent-child bonds.
Pediatrics. 2007;119:182-191.
26. Flohr JW. Musical Lives of Young Children. Prentice Hall;
2005.
27. Jacobsen SL, McKinney CH, Holck U. Effects of a dyadic
music therapy intervention on parent-child interaction, parent
stress, and parent-child relationship in families with emotionally neglected children: a randomized controlled trial. J Music
Ther. 2014;51:310-332.
28. Nicholson JM, Berthelsen D, Abad V, Williams K, Bradley
J. Impact of music therapy to promote positive parenting and child development. J Health Psychol. 2008;13:
226-238.
29. Kazak AE, Baxt C. Families of infants and young children
with cancer: a post-traumatic stress framework. Pediatr Blood
Cancer. 2007;49:1109-1113.
30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde
JG. Research electronic data capture (REDCap)—a metadatadriven methodology and workflow process for providing
translational research informatics support. J Biomed Inform.
2009;42:377-381.
31. Mowbray CT, Nicholson J, Bellamy CD. Psychosocial
rehabilitation service needs of women. Psychiatr Rehabil J.
2003;27:104-113.
32. O’Malley KA, Qualls SH. Application of treatment fidelity
in tailored caregiver interventions. Aging Ment Health. 2020;
24:2094-2102.
33. The American Cancer Society. Acute lymphoblastic leukemia
(ALL). The American Cancer Society; 2018.
34. Henley AK, Collier E, Robertson K, et al. Music therapist
experiences of a randomized controlled trial as clinician
researchers. J Music Ther. 2020;57:315-352.Uncepsentis.

